6. パーキンソン病 Parkinson disease Clinical trials / Disease details
臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04246437 (ClinicalTrials.gov) | February 4, 2020 | 25/1/2020 | [18F]F-DOPA Imaging in Patients With Autonomic Failure | [18F]F-DOPA Imaging in Patients With Autonomic Failure | Autonomic Failure;Pure Autonomic Failure;Parkinson Disease;Multiple System Atrophy;Dementia With Lewy Bodies | Drug: [18F]FDOPA;Drug: Carbidopa 200mg oral dose;Drug: Entacapone 400mg oral dose | Daniel Claassen | NULL | Recruiting | 18 Years | N/A | All | 40 | Phase 1 | United States |
| 2 | NCT02538315 (ClinicalTrials.gov) | October 2016 | 25/8/2015 | Using [18F]FDOPA PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients | Using 3,4-dihydroxy-6-[18F]-Fluoro-l-phenylalanine ( [18F]FDOPA) PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients | Parkinson`s Disease | Drug: [18F]FDOPA PET/CT | University of Saskatchewan | University of Manitoba | Recruiting | 18 Years | N/A | All | 30 | N/A | Canada |